Longer-term, Eisai and Biogen are hoping for further evidence to support Leqembi from the phase 3 AHEAD 3-45 trial, which ...

Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous ...

NHS Wales has signed a memorandum of understanding (MoU) with Illumina to expand an earlier partnership focusing on lung ...

That is the conclusion of the much-anticipated Sudlow Review – carried out by Prof Cathie Sudlow, chief scientist of Health ...

AstraZeneca has revealed that its top executive in China, Leon Wang, has been detained by Chinese authorities, after ...

Just as for previous schemes, metrics are being used to track VPAG, the UK’s voluntary scheme that covers branded medicines ...

VPAG is just the latest iteration of agreements struck between the UK government and industry. The minutes note that, whilst ...

Sales of Elevidys are quickly gaining ground on Sarepta's exon-skipping trio, which need to be dosed chronically. In the ...

Ayvakit has been recommended by NICE for ASM – an umbrella term that covers aggressive systemic mastocytosis, systemic mastocytosis with an associated haematological neoplasm (SM-AHN), and mast cell ...

The Molecular Glue Drug Development Summit returns to Boston with fresh insights and opportunities! With powerhouse ...

Novo Nordisk has abandoned a drug it licensed from KBP Biosciences last year in a deal valued at up to $1.3 billion after it ...

The 6th RNAi-Based Therapeutics Summit is returning to Boston in January 2025 with fresh insights and perspectives.